Reported about 12 hours ago
Amid escalating trade tensions between the U.S. and China, pharmaceutical companies in China, including WuXi AppTec and WuXi Biologics, are adjusting their project plans, stockpiling supplies, and considering local testing of clinical samples to mitigate disruptions. This shift arises from fears of tariff increases and uncertainty in the supply chain, prompting businesses to reconsider their reliance on U.S. imports for essential materials, risking delays in drug development.
Source: YAHOO